Routine board appointment with no immediate trading catalyst. Monitor for any strategic shifts given Cohen's deep healthcare investing background, but no near-term action warranted.
ARWR drugs
ARWR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 17 $81.04entry
- T+1 · 5mo ago +0.96%α +0.18% · $81.82
- T+5 · 5mo ago −1.52%α −0.48% · $79.81
- T+20 · 4mo ago −11.93%α −13.24% · $71.38
- T+60 · 2mo ago +2.23%α −0.92% · $82.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Arrowhead Pharmaceuticals appointed Dr. Matt Cohen, a seasoned healthcare investor and former JP Morgan portfolio manager, to its board of directors effective June 12, 2026. The appointment is routine with standard non-employee director compensation and a sign-on RSU grant of $887,000 vesting over three years.
Key Facts
- Dr. Matt Cohen appointed as director effective June 12, 2026
- Cohen brings 25+ years of healthcare investing experience, currently Managing Director at Vida Ventures
- Sign-on RSU grant valued at $887,000 vesting over three years
- Standard non-employee director compensation; no family relationships or arrangements
Financial Impact
No material financial impact; sign-on RSU grant of $887,000 is standard director compensation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000879407-26-000050 |
| Document: 0000879407-26-000050-index-headers.html | 0000879407-26-000050 |
| Document: 0000879407-26-000050-index.html | 0000879407-26-000050 |
| Document: 0000879407-26-000050.txt | 0000879407-26-000050 |
Track record
7 reports on ARWR
1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +17.69% at T+5 after the Nov 2, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $47.78 to $44.21 Now $44.21 +7.47% ▲ +7.47% +5.56% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $57.46 to $58.16 Now $44.21 −23.06% ▲ +1.22% +0.91% vs SPY
- Nov 4, 202612d ago 8-K Bullish 5/10 Entry $61.65 to $57.46 Now $44.21 −28.29% ▼ −6.80% −2.39% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $59.53 to $61.65 Now $44.21 +25.73% ▼ −3.56% −1.91% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $82.76 to $82.85 Now $44.21 −46.58% ▲ +0.11% −0.74% vs SPY
- Aug 20, 202612w ago Insider Cluster Neutral 2/10 Entry $87.11 to $86.73 Now $44.21 −49.25% ▼ −0.44% −0.14% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Viewing Entry $81.04 to $81.82 Now $44.21 −45.45% ▲ +0.96% +0.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers